India · Delayed Price · Currency is INR Alivus Life Sciences Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profitability grew strongly in FY 2026, driven by non-GPL and CDMO segments, margin expansion, and disciplined cost management. CapEx is fully funded internally, with new capacity and backward integration expected to support future growth.
-
Record Q3FY26 revenue and margins were driven by strong CDMO recovery, new launches, and operational efficiencies. Capacity expansions are on track, with high single-digit revenue growth and 30%-32% margins guided for FY26. Cash flow and balance sheet remain robust.
-
Q2 FY 2026 saw 16% YoY revenue growth to INR 588 crore, with gross and EBITDA margins rising to 57.7% and 33%, respectively. Non-GPL and new product launches drove growth, while CDMO and GPL are set for H2 recovery. CapEx is below plan, but expansion projects and cash reserves remain strong.
-
Q1 FY26 saw 2.2% YoY revenue growth to INR 602 crore, with strong margins and robust cash flow. Non-GPL business led growth, while GPL is expected to recover in H2. CDMO ramp-up and new launches support a positive outlook, with margins guided at 28–30%.
Fiscal Year 2025
-
Q4 FY2025 saw 21.1% revenue growth and a 32.1% EBITDA margin, with broad-based gains across geographies and segments. FY2026 guidance points to mid-teens volume growth but high single-digit revenue growth due to price erosion, with margins expected to remain in the 28%-30% range.
-
Q3 FY25 saw 12% YoY and 27% QoQ revenue growth, with strong generic and CDMO performance, robust margins, and continued investment in R&D and capacity. Outlook remains positive, with new launches expected to drive future growth and surplus cash allocated to expansion and innovation.
-
Q2 FY2025 saw a 14.9% YoY revenue decline due to a temporary production halt, but gross margins improved to 55.6% and EBITDA margin to 28.2%. FY2025 revenue growth is now guided at high single digits, with strong H2 recovery expected and new CDMO projects set to drive future growth.
-
Q1 FY 2025 saw a strong sequential recovery with 9.7% revenue growth and stable EBITDA margins, despite gross margin pressure from the loss of PLI benefits. Capacity expansions and a robust CDMO pipeline support a positive outlook, while a pollution-related closure at Ankleshwar is expected to be resolved quickly.